The Development and Clinical Testing of New Anticancer Drugs at the National Cancer Institute — Example cis-Platinum (II) Diamminedichloride (NSC 119 875)-Reference-Cited by-同舟云学术

The Development and Clinical Testing of New Anticancer Drugs at the National Cancer Institute — Example cis-Platinum (II) Diamminedichloride (NSC 119 875)

Published:1974 Issue: Volume: Page:137-144
ISSN:0080-0015
Container-title:Recent Results in Cancer Research
language:
Short-container-title:

Author:

Carter S. K.,Goldsmith M.

Publisher

Springer Berlin Heidelberg

Link

http://link.springer.com/content/pdf/10.1007/978-3-642-49306-5_9.pdf

Reference10 articles.

1. Dixon, R. L.: Laboratory of toxicology. Cancer Chemother. Rep. 2 (3), 61 (1971).

2. Freireich, E. J., Gehan, E. A., RALL, D. P., SCHMIDT, L. H., SKIPPER, H. E.: Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. 50, 219 (1966).

3. Hansen, H. H.: Clinical experience with 1-(2-chloroethyl)3-cyclohexyl-1-nitrosourea (CCNU, NSC 79 037). Proc. Amer. Ass. Cancer Res. (Abstr.) 11, 87 (1970).

4. Muggia, F. M.: Phase I study of 4’ demethyl-epipodophyllotoxin-B-D-thenylidene glycoside (PTG, NSC 122 819). Proc. Amer. Ass. Cancer Res. (Abstr.) 11, 58 (1970).

5. Pinkel, D.: The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res. 18, 853 (1958).

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical study of a new antimetastatic compound, Nafazatrom (Bay g 6575). Effects on platelet consumption and monocyte prostaglandin production in patients with advanced cancer;Cancer;1986-04-15

2. Biological Activities of cis-Dichlorodiamineplatinum II and Its Derivatives;Bioactive Polymeric Systems;1985

3. Cisplatin — Past, Present and Future;Platinum Coordination Complexes in Cancer Chemotherapy;1984

4. High dose Cis-platinum diammine dichloride.Amelioration of renal toxicity by mannitol diuresis;Cancer;1977-04